New viral vector vaccine
For Ebola. New vaccines for Bundibugyo ebolavirus
ChAdOx1 Bundibugyo vaccine (Oxford / Serum Institute)
Uses the chimpanzee adenovirus (ChAdOx1) platform
Similar technology was used in the Oxford AZ COVID-19 vaccine
Potentially be ready for early efficacy assessment in 2–3 months
How the ChAdOx system works
Genes for the antigen are inserted into a viral vector
Injection(im)
Biodistribution
Cell entry
Delivers DNA instructions into the cell
Antigen production
Cell manufactures the viral protein:
Both cause human cells to manufacture a viral antigen
COVID vaccine → spike protein
Ebola vaccine → Ebola glycoprotein
For the SARS-CoV-2, spike protein, immunologically important antigen, is believed to be associated with cells surfaces rather than freely circulating.
